Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046852 · ClinicalTrials.gov registry record · Phase 1

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm and Infection, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Phase 1
Development phase
2
Study locations

NCT00046852 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm and Infection that has completed, run by University of Maryland, Baltimore. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046852, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm and Infection, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Phase 1
Development phase
2
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Randomized phase I/II trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation followed by immunotherapy in treating patients who have multiple myeloma.

Conditions Studied

Multiple Myeloma and Plasma Cell Neoplasm Infection

Interventions

  • DRUG carmustine
  • BIOLOGICAL therapeutic autologous lymphocytes
  • BIOLOGICAL filgrastim
  • BIOLOGICAL therapeutic tumor infiltrating lymphocytes
  • BIOLOGICAL pneumococcal polyvalent vaccine

Study Locations (2)

Maryland

  • Marlene and Stewart Greenebaum Cancer Center, University of Maryland - Baltimore

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Start Date 2001-12
Est. Completion 2008-02
Phase Phase 1

Sponsor

University of Maryland, Baltimore

560 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00046852

The ClinicalTrials.gov registry entry for NCT00046852 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which carmustine is the first listed.

NCT00046852 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00046852 about?

NCT00046852 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer ...

What is the current status of trial NCT00046852?

This trial is currently completed. It is a Phase 1 study. The study started on 2001-12. Estimated completion is 2008-02.

What conditions does trial NCT00046852 study?

This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm, Infection.

What interventions are being tested in trial NCT00046852?

The interventions under investigation include: carmustine (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), filgrastim (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL), pneumococcal polyvalent vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00046852?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00046852 being conducted?

This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma and Plasma Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma and Plasma Cell Neoplasm

All registered trials for this condition

Infection

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.